The FDA has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adults with treatment-resistant depression.

Longitudinal data shows increasing or high addictive use of social media and mobile phones in adolescents significantly raises the risk of suicidal behaviors and ideation.

The FDA has approved Uzedy (risperidone) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

(HealthDay News) — Brief bouts of exercise spread throughout the day (“exercise snacks”) improve cardiorespiratory fitness in physically inactive adults, according to a review published online in the ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adults.

(HealthDay News) — The risk for amyotrophic lateral sclerosis (ALS) is higher in the 2 years after a traumatic brain injury (TBI), according to a study published online Oct. 2 in JAMA Network Open.

Study details the association between sedative-hypnotic prescriptions, high volume, and recent use with increased suicide risk and self-poisoning in older adults.

The FDA has granted Fast Track designation to CS-1103 for the treatment of acute methamphetamine intoxication.

Resilience training (RT), a brief mindfulness-based intervention, reduced early psychopathology, emotion reactivity, and altered hippocampal-prefrontal brain connectivity in at-risk young adults.

CVD DALYs reported globally in 2023, representing a 1.4-fold increase from 1990; increase in number of CVD deaths also seen.

Among children with and without chronic conditions, the weighted prevalence of food insecurity was 14.8 and 9.0 percent, respectively, across the study period. After controlling for family and child ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.